STOCK TITAN

PROVECTUS BIOPHARMACEUTICALS (PVCT) SEC Filings, Apr-Jun 2026

PVCT OTC
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing exercised convertible securities to increase his common stock holdings. On the transactions date, an 8% unsecured convertible promissory note converted into 9,436 shares of Series D-1 Convertible Preferred Stock at $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 94,360 additional common shares. After these derivative exercises and conversions, Pershing directly owns 2,857,285 shares of common stock. These were conversions of existing securities, not open-market purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
insider
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note as a derivative award. The note can be converted into Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, with 5,242 preferred shares issuable on conversion. The note’s principal and interest will automatically convert into Series D-1 Preferred Stock twelve months after its issue date. Each Series D-1 Preferred share is itself convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities to acquire additional common stock. An 8% unsecured convertible promissory note converted into 32,089 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, then those preferred shares converted into 320,890 shares of common stock. Following these conversions, Pershing directly holds 2,847,849 shares of common stock. These were non‑market derivative conversions, not open‑market purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-market transaction that increases his common stock position through derivative conversions. An 8% unsecured convertible promissory note was converted into 22,651 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, as described in the financing terms. Each preferred share is convertible into 10 shares of common stock, resulting in 226,510 common shares underlying this conversion. Following these exercises and conversions, Pershing directly holds 2,815,760 shares of common stock, reflecting a larger equity stake obtained through previously agreed financing and conversion features rather than open-market purchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
insider
-
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. reported a net loss of $1.3 million for the three months ended March 31, 2026, compared with $1.16 million a year earlier. Grant revenue fell from $278,628 to zero as a prior Tennessee grant was fully recognized in 2025.

Research and development expenses declined 17.2% to $333,334, and general and administrative costs decreased 6.1% to $914,569, reflecting lower clinical activity, professional fees, and stock-based compensation, partly offset by higher legal and software costs. Cash was $223,883 at March 31, 2026, with a working capital deficit of $6.78 million and an accumulated deficit of $264.1 million.

The company discloses that these conditions raise substantial doubt about its ability to continue as a going concern and states it must secure additional financing, including through its 2025 unsecured convertible notes program, equity offerings, or collaborations to fund operations and planned clinical development of its RBS-based drug candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.30%
Tags
quarterly report
-
Rhea-AI Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities related to prior financing arrangements. An 8% unsecured convertible promissory note converted into 18,876 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 188,760 shares of common stock. Following these conversions, Pershing held 2,793,109 shares of common stock directly, with no remaining derivative position from this note.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
annual report
-
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. is asking stockholders to approve several key corporate and governance items at its 2026 annual meeting. The in‑person meeting is scheduled for June 18, 2026 in Knoxville, Tennessee, with a record date of April 20, 2026.

Stockholders will vote to elect four directors, approve on an advisory basis the compensation of named executive officers, and ratify CBIZ CPAs P.C. as independent auditor for 2026. The proxy details executive pay, including 2025 base salaries of $240,000 for the CEO and President and $200,000 for the CFO, plus prior large stock option grants under the 2024 Equity Compensation Plan.

The most structural proposals would authorize the board to implement a reverse stock split of common stock, Series D Preferred, and Series D‑1 Preferred at a ratio between 1‑for‑10 and 1‑for‑50, and, only if that split is approved, to proportionally reduce authorized common and preferred shares. As of the record date, there were 420,279,879 common shares outstanding, along with 956,985 Series D and 14,389,027 Series D‑1 shares. The board unanimously recommends voting “FOR” all five proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
proxy
-
Rhea-AI Summary

Provectus Biopharmaceuticals CEO Edward Pershing reported a non-cash conversion of debt into equity. An 8% unsecured convertible promissory note automatically converted into 30,202 shares of Series D-1 Convertible Preferred Stock on April 29, 2026 at a conversion price of $2.862 per share.

Each Series D-1 preferred share is convertible into 10 shares of common stock, so the new preferred position represents 302,020 common shares. After this derivative exercise/conversion, Pershing directly owns 2,774,233 shares of Provectus common stock, with no remaining derivative position shown in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
insider
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. is scheduling its 2026 Annual Meeting of Stockholders for June 18, 2026 at 4:00 p.m. Eastern Time at Perkins Place in Knoxville, Tennessee, which is planned to become the company’s new headquarters.

The company intends to relocate from its current offices at 800 S. Gay Street, Suite 1610, to Perkins Place in 2026. April 20, 2026 is the record date, and stockholders will receive a notice of internet availability with instructions to access the definitive proxy materials.

Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on rose bengal sodium, with programs in oncology, dermatology, ophthalmology, and several additional proof-of-concept areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.20%
Tags
current report

FAQ

How many PROVECTUS BIOPHARMACEUTICALS (PVCT) SEC filings are available on StockTitan?

StockTitan tracks 65 SEC filings for PROVECTUS BIOPHARMACEUTICALS (PVCT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for PROVECTUS BIOPHARMACEUTICALS (PVCT)?

The most recent SEC filing for PROVECTUS BIOPHARMACEUTICALS (PVCT) was filed on November 16, 2026.